BioLife Solutions, Inc.
BLFS
$25.41
-$1.09-4.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.21% | 28.94% | 29.88% | 44.21% | -9.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.21% | 28.94% | 29.88% | 44.21% | -9.26% |
| Cost of Revenue | 37.11% | 38.11% | 31.70% | 22.38% | -36.09% |
| Gross Profit | 28.09% | 24.43% | 28.96% | -7.38% | 16.64% |
| SG&A Expenses | 23.40% | 19.72% | 10.37% | 2.17% | -24.58% |
| Depreciation & Amortization | 2.34% | 3.66% | 2.03% | 100.49% | -47.94% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.10% | 26.27% | 15.79% | 44.76% | -32.52% |
| Operating Income | 78.71% | 14.09% | 63.03% | -46.07% | 95.22% |
| Income Before Tax | 227.59% | -182.64% | 86.36% | -86.42% | 96.49% |
| Income Tax Expenses | 202.50% | 12,500.00% | -17.65% | 43.78% | -169.57% |
| Earnings from Continuing Operations | 231.85% | -184.86% | 86.00% | -85.56% | 97.02% |
| Earnings from Discontinued Operations | -- | -- | -- | 140.62% | 90.76% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 136.47% | 23.56% | 95.62% | 183.30% | 94.15% |
| EBIT | 78.71% | 14.09% | 63.03% | -46.07% | 95.22% |
| EBITDA | -34.39% | -75.38% | 116.32% | -44.30% | 134.11% |
| EPS Basic | 135.23% | 26.42% | 95.78% | 180.04% | 94.48% |
| Normalized Basic EPS | 222.67% | 87.62% | 86.76% | -43.75% | 94.16% |
| EPS Diluted | 127.10% | 26.42% | 95.78% | 176.93% | 94.48% |
| Normalized Diluted EPS | 220.00% | 87.62% | 86.76% | -45.38% | 94.16% |
| Average Basic Shares Outstanding | 3.79% | 3.90% | 3.75% | 4.07% | 5.98% |
| Average Diluted Shares Outstanding | 5.52% | 3.90% | 3.75% | 7.16% | 5.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |